COVID-19 Therapeutics in 2022: Advances and Controversies in Evidence, Oversight, Accessibility and Utility of Therapy

Saturday, February 26, 2022

9:00 am -1:10 pm ET

The Mayo Clinic School of Continuous Professional Development is hosting an interactive livestream CME event:

COVID-19 Therapeutics in 2022: Advances and Controversies in Evidence, Oversight, Accessibility, and Utility of Therapy Livestream

 

You must register at the website to participate.

 

In this interactive livestream event, course directors DeLisa Fairweather, Ph.D., Michael J. Joyner, M.D., R. Scott Wright, M.D., and leading experts from Mayo Clinic, Johns Hopkins, and the U.S. Food and Drug Administration will address a variety of topics related to COVID-19 Therapeutics in 2022 including:

  • The evolving utility of convalescent plasma in COVID-19 patients
  • Monoclonal antibody therapy for at risk patients
  • Insights from building and managing the Mayo Clinic infusion program
  • Lessons learned from the pandemic
  • Review of the latest data regarding the safety, efficacy, and future directions of vaccination for COVID-19 prevention
  • Panel questions and discussion

Target Audience

This activity is intended for healthcare providers treating patients with COVID-19. It is designed for physicians, scientist researcher PhDs, physician assistants, nurse practitioners, nurses, pharmacists, residents, fellows and students.

Learning Objectives

  • Review the use of convalescent plasma for treatment of COVID-19 patients.
  • Describe how to make use of convalescent plasma for treatment of COVID-19 patients and how this has changed over the past year.
  • Discuss the current outcomes data for the use of convalescent plasma for treatment of COVID-19 patients.
  • Give examples of support options for clinicians for the use of plasma and resources for sending their patients to donate.
  • Describe criteria to select patients that would benefit from monoclonal antibody infusions.
  • Interpret the safety and efficacy of the COVID-19 vaccination so that one can educate and reassure the public and encourage vaccination.

Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s): 

AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Healthcare Professionals:
A record of attendance will be provided to all registrants for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.

Available Credit

  • 3.75 AMA PRA Category 1 Credit
  • 3.75 ANCC
  • 3.75 Attendance

Location: https://ce.mayo.edu/internal-medicine/content/covid-19-therapeutics-2022-advances-and-controversies-evidence-oversight-accessibility-and-2